Equities

Hims & Hers Health Inc

Hims & Hers Health Inc

Actions
Health CareHealth Care Providers
  • Price (USD)16.92
  • Today's Change0.61 / 3.74%
  • Shares traded6.79m
  • 1 Year change+171.15%
  • Beta1.0398
Data delayed at least 15 minutes, as of Sep 20 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform4
Hold8
Sell0
Strong Sell0

Share price forecast in USD

The 14 analysts offering 12 month price targets for Hims & Hers Health Inc have a median target of 22.00, with a high estimate of 30.00 and a low estimate of 16.00. The median estimate represents a 30.02% increase from the last price of 16.92.
High77.3%30.00
Med30.0%22.00
Low-5.4%16.00

Earnings history & estimates in USD

On Aug 05, 2024, Hims & Hers Health Inc reported 2nd quarter 2024 earnings of 0.06 per share. This result was in line with the consensus of the 11 analysts following the company and outperformed last year's 2nd quarter results by 0.09.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+128.89%
Hims & Hers Health Inc reported annual 2023 losses of -0.11 per share on Feb 26, 2024.
Average growth rate-5.26%
More ▼

Revenue history & estimates in USD

Oaktree Acquisition Corp. had 2nd quarter 2024 revenues of 315.65m. This bettered the 299.94m consensus of the 12 analysts covering the company. This was 65.46% above the prior year's 2nd quarter results.
Average growth rate+11.02%
Oaktree Acquisition Corp. had revenues for the full year 2023 of 878.00m. This was 66.63% above the prior year's results.
Average growth rate+81.07%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.